Teva Pharmaceutical Industries Ltd. $TEVA Shares Bought by Bellevue Group AG

Bellevue Group AG lifted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 1,357.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 421,501 shares of the company’s stock after buying an additional 392,571 shares during the period. Bellevue Group AG’s holdings in Teva Pharmaceutical Industries were worth $7,064,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Advisors Asset Management Inc. acquired a new position in Teva Pharmaceutical Industries in the second quarter valued at $41,000. Sound Income Strategies LLC increased its position in shares of Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after purchasing an additional 2,824 shares in the last quarter. MAI Capital Management lifted its holdings in shares of Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after purchasing an additional 697 shares during the last quarter. Brooklyn Investment Group boosted its position in shares of Teva Pharmaceutical Industries by 403.4% in the 1st quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock valued at $77,000 after purchasing an additional 4,014 shares during the period. Finally, CWM LLC boosted its position in shares of Teva Pharmaceutical Industries by 18.1% in the 2nd quarter. CWM LLC now owns 4,995 shares of the company’s stock valued at $84,000 after purchasing an additional 767 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on TEVA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Barclays started coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday. They set an “overweight” rating and a $35.00 target price on the stock. Scotiabank initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price target for the company. The Goldman Sachs Group increased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $30.25.

Teva Pharmaceutical Industries Stock Down 1.3%

Shares of NYSE:TEVA opened at $29.80 on Friday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $30.20. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The firm’s 50-day simple moving average is $23.43 and its 200-day simple moving average is $19.60. The company has a market cap of $34.18 billion, a price-to-earnings ratio of 49.67, a PEG ratio of 1.79 and a beta of 0.67.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the completion of the sale, the director directly owned 495,000 shares of the company’s stock, valued at $11,934,450. This trade represents a 28.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the sale, the insider owned 52,828 shares in the company, valued at approximately $1,517,748.44. This trade represents a 80.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 532,360 shares of company stock valued at $14,364,929. 0.49% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.